Literature DB >> 17032898

A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000.

Sylvia K Plevritis1, Bronislava M Sigal, Peter Salzman, Jarrett Rosenberg, Peter Glynn.   

Abstract

BACKGROUND: We present a simulation model that predicts U.S. breast cancer mortality trends from 1975 to 2000 and quantifies the impact of screening mammography and adjuvant therapy on these trends. This model was developed within the Cancer Intervention and Surveillance Network (CISNET) consortium.
METHOD: A Monte Carlo simulation is developed to generate the life history of individual breast cancer patients by using CISNET base case inputs that describe the secular trend in breast cancer risk, dissemination patterns for screening mammography and adjuvant treatment, and death from causes other than breast cancer. The model generates the patient's age, tumor size and stage at detection, mode of detection, age at death, and cause of death (breast cancer versus other) based in part on assumptions on the natural history of breast cancer. Outcomes from multiple birth cohorts are summarized in terms of breast cancer mortality rates by calendar year. RESULT: Predicted breast cancer mortality rates follow the general shape of U.S. breast cancer mortality rates from 1975 to 1995 but level off after 1995 as opposed to following an observed decline. Sensitivity analysis revealed that the impact adjuvant treatment may be underestimated given the lack of data on temporal variation in treatment efficacy.
CONCLUSION: We developed a simulation model that uses CISNET base case inputs and closely, but not exactly, reproduces U.S. breast cancer mortality rates. Screening mammography and adjuvant therapy are shown to have both contributed to a decline in U.S. breast cancer mortality.

Entities:  

Mesh:

Year:  2006        PMID: 17032898     DOI: 10.1093/jncimonographs/lgj012

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  19 in total

1.  Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.

Authors:  Jeanne S Mandelblatt; Natasha K Stout; Clyde B Schechter; Jeroen J van den Broek; Diana L Miglioretti; Martin Krapcho; Amy Trentham-Dietz; Diego Munoz; Sandra J Lee; Donald A Berry; Nicolien T van Ravesteyn; Oguzhan Alagoz; Karla Kerlikowske; Anna N A Tosteson; Aimee M Near; Amanda Hoeffken; Yaojen Chang; Eveline A Heijnsdijk; Gary Chisholm; Xuelin Huang; Hui Huang; Mehmet Ali Ergun; Ronald Gangnon; Brian L Sprague; Sylvia Plevritis; Eric Feuer; Harry J de Koning; Kathleen A Cronin
Journal:  Ann Intern Med       Date:  2016-01-12       Impact factor: 25.391

2.  Modeling the impact of population screening on breast cancer mortality in the United States.

Authors:  Jeanne S Mandelblatt; Kathleen A Cronin; Donald A Berry; Yaojen Chang; Harry J de Koning; Sandra J Lee; Sylvia K Plevritis; Clyde B Schechter; Natasha K Stout; Nicolien T van Ravesteyn; Marvin Zelen; Eric J Feuer
Journal:  Breast       Date:  2011-10       Impact factor: 4.380

Review 3.  Calibration methods used in cancer simulation models and suggested reporting guidelines.

Authors:  Natasha K Stout; Amy B Knudsen; Chung Yin Kong; Pamela M McMahon; G Scott Gazelle
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

4.  Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.

Authors:  Diego Munoz; Aimee M Near; Nicolien T van Ravesteyn; Sandra J Lee; Clyde B Schechter; Oguzhan Alagoz; Donald A Berry; Elizabeth S Burnside; Yaojen Chang; Gary Chisholm; Harry J de Koning; Mehmet Ali Ergun; Eveline A M Heijnsdijk; Hui Huang; Natasha K Stout; Brian L Sprague; Amy Trentham-Dietz; Jeanne S Mandelblatt; Sylvia K Plevritis
Journal:  J Natl Cancer Inst       Date:  2014-09-24       Impact factor: 13.506

5.  Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.

Authors:  Allison W Kurian; Bronislava M Sigal; Sylvia K Plevritis
Journal:  J Clin Oncol       Date:  2009-12-07       Impact factor: 44.544

6.  To screen or not to screen for breast cancer? How do modelling studies answer the question?

Authors:  R G Koleva-Kolarova; Z Zhan; M J W Greuter; T L Feenstra; G H De Bock
Journal:  Curr Oncol       Date:  2015-10       Impact factor: 3.677

7.  Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis.

Authors:  Marc D Ryser; Mathias Worni; Elizabeth L Turner; Jeffrey R Marks; Rick Durrett; E Shelley Hwang
Journal:  J Natl Cancer Inst       Date:  2015-12-17       Impact factor: 13.506

8.  A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.

Authors:  Bronislava M Sigal; Diego F Munoz; Allison W Kurian; Sylvia K Plevritis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-05-03       Impact factor: 4.254

9.  Online tool to guide decisions for BRCA1/2 mutation carriers.

Authors:  Allison W Kurian; Diego F Munoz; Peter Rust; Elizabeth A Schackmann; Michael Smith; Lauren Clarke; Meredith A Mills; Sylvia K Plevritis
Journal:  J Clin Oncol       Date:  2012-01-09       Impact factor: 44.544

10.  Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms.

Authors:  Jeanne S Mandelblatt; Kathleen A Cronin; Stephanie Bailey; Donald A Berry; Harry J de Koning; Gerrit Draisma; Hui Huang; Sandra J Lee; Mark Munsell; Sylvia K Plevritis; Peter Ravdin; Clyde B Schechter; Bronislava Sigal; Michael A Stoto; Natasha K Stout; Nicolien T van Ravesteyn; John Venier; Marvin Zelen; Eric J Feuer
Journal:  Ann Intern Med       Date:  2009-11-17       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.